Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Telangiectasia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    58 result(s) found for: Telangiectasia. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2017-003272-31 Sponsor Protocol Number: NL.EPITRAC.0107.17 Start Date*: 2018-05-18
    Sponsor Name:St. Antonius Ziekenhuis
    Full Title: Efficacy and safety of oral itraconazole in the reduction of epistaxis severity in hereditary hemorrhagic telangiectasia
    Medical condition: Severe epistaxis in patients with Hereditary Hemorrhagic Telangiectasia also known as Rendu-Osler-Weber disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10031132 Osler-Weber-Rendu disease LLT
    20.0 100000004850 10038554 Rendu-Osler-Weber syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003982-24 Sponsor Protocol Number: HHT-HOPE-2016 Start Date*: 2017-03-16
    Sponsor Name:Asociación HHT España
    Full Title: A phase IV-II, single-center, open, single arm treatment, low level of intervention, to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of...
    Medical condition: Hereditary hemorrhagic telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10020023 HHT LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004096-36 Sponsor Protocol Number: THALI-HHT Start Date*: 2011-10-11
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Efficacy of thalidomide in the treatment of severe recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT)
    Medical condition: Severe recurrent epistaxis in hereditary hemorrhagic telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10038554 Rendu-Osler-Weber syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004010-26 Sponsor Protocol Number: THR-317-003 Start Date*: 2018-08-03
    Sponsor Name:ThromboGenics NV
    Full Title: A Phase 2, open-label, multi-centre study to assess the efficacy and safety of intravitreal THR-317 for the treatment of macular telangiectasia Type 1 (MacTel 1)
    Medical condition: Macular Telangiectasia Type 1 (MacTel 1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10038899 Retinal telangiectasia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004789-27 Sponsor Protocol Number: 21.November.2015 Start Date*: 2016-03-03
    Sponsor Name:Bispebjerg Hospital
    Full Title: Topical brimonidine to reduce post-inflammatory response after IPL- treatment and effect on IPL-efficacy in patients with facial telangiectasias
    Medical condition: Inflammation after IPL-treatment in patients with facial telangiectasias
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10043189 Telangiectasia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-022315-19 Sponsor Protocol Number: IEDAT-ERY01-2010 Start Date*: 2011-01-11
    Sponsor Name:ERYDEL S.P.A.
    Full Title: Valutazione degli effetti del Desametasone Sodio Fosfato Intra-Eritrocitario sui Sintomi Neurologici in Pazienti con Atassia Teleangectasia
    Medical condition: Patients with Ataxia-Teleangectasia (AT)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003594 LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000385-55 Sponsor Protocol Number: 69HCL15_0063 Start Date*: 2015-05-12
    Sponsor Name:Hospices Civils de Lyon
    Full Title: TEMPO : Efficacité du TIMOLOL en administration nasale pour le traitement des épistaxis dans la maladie de Rendu-Osler. Essai randomisé en double insu contre placebo
    Medical condition: Rendu-Osler disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004204-19 Sponsor Protocol Number: 2013-827 Start Date*: 2014-02-26
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler
    Medical condition: Rendu-Osler disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000338-36 Sponsor Protocol Number: IEDAT-03-2018 Start Date*: 2018-05-31
    Sponsor Name:EryDel S.p.A.
    Full Title: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study
    Medical condition: Patient with neurological symptoms of Ataxia Telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10003594 Ataxia telangiectasia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) PL (Completed) GB (GB - no longer in EU/EEA) NO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005241-31 Sponsor Protocol Number: IEDAT-02-2015 Start Date*: 2016-09-14
    Sponsor Name:EryDel S.p.A.
    Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telan...
    Medical condition: Patient with neurological symptoms of Ataxia Telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10003594 Ataxia telangiectasia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NO (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006233-40 Sponsor Protocol Number: CRFB002ADE04 Start Date*: 2007-08-06
    Sponsor Name:Department of Ophthalmology, Bonn University
    Full Title: Ranibizumab in idiopathic macular telangiectasia, type2 A prospective interventional non-randomized study comparing the efficacy and safety of intravitreal ranibizumab (dosing regimen 0.5mg every ...
    Medical condition: Typical findings in Type 2 idiopathic macular telangiectasia (type2-IMT)are parafoveal ectatic capillaries, The disease is characterized by a slow decrease in visual acuity, reading difficulties an...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064761 Parafoveal telangiectasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006755-44 Sponsor Protocol Number: 2008-510 Start Date*: 2009-01-15
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II
    Medical condition: Maladie de Rendu-Osler
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004539-57 Sponsor Protocol Number: Dio/01/2013 Start Date*: 2014-01-30
    Sponsor Name:ALIO MEDICA Sp. z o.o.
    Full Title: A phase III, double-blind, placebo-controlled, randomized, three-arm parallel, study assessing efficacy and safety of 4 months of diosmin administration for the treatment of lower extremity teleang...
    Medical condition: lower extremity teleangiectasias and gynoid lipodystrophy (edematous fibrosclerotic panniculopathy commonly known as cellulite)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004858 10065339 Cellulite LLT
    17.0 100000004858 10043193 Telangiectasis LLT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004122-70 Sponsor Protocol Number: 04M107 Start Date*: 2005-11-15
    Sponsor Name:Great Ormond Street Hospital
    Full Title: Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine.
    Medical condition: Ataxia Telangiectasia (AT) is a genetic condition in which there is a deficiency of the immune system with excessive susceptibility to pneumonia and other infections.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003585-40 Sponsor Protocol Number: NL.TACRO.10.7.19 Start Date*: 2019-12-17
    Sponsor Name:St. Antonius Hospital
    Full Title: An uncontrolled, open label pilot-study assessing the efficacy in reducing bleeding severity, and the safety of oral tacrolimus in patients with hereditary hemorrhagic telangiectasia
    Medical condition: Gastrointestinal bleeding and epistaxis caused by hereditary hemorrhagic telangiectasia. Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant inherited disease characterized by muco...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10038554 Rendu-Osler-Weber syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004179-11 Sponsor Protocol Number: 2018-4898 Start Date*: 2019-06-03
    Sponsor Name:Radboudumc
    Full Title: Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, pa...
    Medical condition: Hereditary hemorrhagic telangiectasia (HHT)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Ongoing) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003260-12 Sponsor Protocol Number: NTMT-03-B Start Date*: 2018-10-02
    Sponsor Name:Neurotech Pharmaceuticals Inc.
    Full Title: A Phase 3 Multicenter Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia type 2
    Medical condition: Macular Telangiectasia type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001031-39 Sponsor Protocol Number: 69HCL17_0018 Start Date*: 2017-05-19
    Sponsor Name:Hospices Civils de Lyon
    Full Title: BABH Study: Efficacy and safety of bevacizumab on severe bleedings associated with Hemorrhagic Hereditary Telangiectasia (HHT). A National, randomized multicenter phase III study.
    Medical condition: Hemorrhagic Hereditary Telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003234-82 Sponsor Protocol Number: NTMT-03-A Start Date*: 2018-06-13
    Sponsor Name:Neurotech Pharmaceuticals
    Full Title: A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia type 2
    Medical condition: Macular Telangiectasia type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004407-39 Sponsor Protocol Number: IB1001-203 Start Date*: 2019-09-18
    Sponsor Name:IntraBio Ltd.
    Full Title: Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A multinational, multicenter, open-label, rater-blinded Phase II study.
    Medical condition: To demonstrate that N-Acetyl-L-Leucine is effective in improving symptoms, functioning, and quality of life in patients with Ataxia-Telangiectasia (A-T)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 01:04:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA